SARAH GAUDIOSI: Open Payments
NPI 1518385897 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$805 in 45 payments from 10 companies in 2025. Trend: 2023 $602 · 2024 $631 · 2025 $805
Food & beverage: $805
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $238 |
| Madrigal Pharmaceuticals | 3 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Janssen Biotech, Inc. | 5 | $102 |
| Regeneron Healthcare Solutions, Inc. | 2 | $70 |
| GENZYME CORPORATION | 2 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| Intercept Pharmaceuticals, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 3 | $34 |
| Braintree Laboratories, Inc. | 1 | $18 |
Products named: DUPIXENT, RINVOQ, REZDIFFRA, TREMFYA, ENTYVIO, ZENPEP, LINZESS, MAVYRET.
Industry payments across FL — which companies pay providers there.
